Glioma targeted therapy: insight into future of molecular approaches

K Yang, Z Wu, H Zhang, N Zhang, W Wu, Z Wang… - Molecular Cancer, 2022 - Springer
Gliomas are the common type of brain tumors originating from glial cells. Epidemiologically,
gliomas occur among all ages, more often seen in adults, which males are more susceptible …

Enhancing immunotherapy in cancer by targeting emerging immunomodulatory pathways

L Kraehenbuehl, CH Weng, S Eghbali… - Nature reviews Clinical …, 2022 - nature.com
The discovery and clinical implementation of immune-checkpoint inhibitors (ICIs) targeting
CTLA4, PD-1 and PD-L1 has revolutionized the treatment of cancer, as recognized by the …

Immune checkpoint modulators in cancer immunotherapy: recent advances and emerging concepts

Y Wang, H Zhang, C Liu, Z Wang, W Wu… - Journal of Hematology & …, 2022 - Springer
The discovery of immune checkpoint inhibitors (ICIs) has now been universally
acknowledged as a significant breakthrough in tumor therapy after the targeted treatment of …

Signal pathways of melanoma and targeted therapy

W Guo, H Wang, C Li - Signal transduction and targeted therapy, 2021 - nature.com
Melanoma is the most lethal skin cancer that originates from the malignant transformation of
melanocytes. Although melanoma has long been regarded as a cancerous malignancy with …

Immunotherapy in lung cancer: current landscape and future directions

H Mamdani, S Matosevic, AB Khalid, G Durm… - Frontiers in …, 2022 - frontiersin.org
Over the past decade, lung cancer treatment has undergone a major paradigm shift. A
greater understanding of lung cancer biology has led to the development of many effective …

APOE4 impairs the microglial response in Alzheimer's disease by inducing TGFβ-mediated checkpoints

Z Yin, N Rosenzweig, KL Kleemann, X Zhang… - Nature …, 2023 - nature.com
The APOE4 allele is the strongest genetic risk factor for late-onset Alzheimer's disease (AD).
The contribution of microglial APOE4 to AD pathogenesis is unknown, although APOE has …

Galectin-9 interacts with PD-1 and TIM-3 to regulate T cell death and is a target for cancer immunotherapy

R Yang, L Sun, CF Li, YH Wang, J Yao, H Li… - Nature …, 2021 - nature.com
The two T cell inhibitory receptors PD-1 and TIM-3 are co-expressed during exhausted T cell
differentiation, and recent evidence suggests that their crosstalk regulates T cell exhaustion …

Mechanisms of immune activation and regulation: lessons from melanoma

S Kalaora, A Nagler, JA Wargo, Y Samuels - Nature Reviews Cancer, 2022 - nature.com
Melanoma, a skin cancer that develops from pigment cells, has been studied intensively,
particularly in terms of the immune response to tumours, and has been used as a model for …

The future of cancer immunotherapy: microenvironment-targeting combinations

YR Murciano-Goroff, AB Warner, JD Wolchok - Cell research, 2020 - nature.com
Immunotherapy holds the potential to induce durable responses, but only a minority of
patients currently respond. The etiologies of primary and secondary resistance to …

[HTML][HTML] Targeted nanomedicines remodeling immunosuppressive tumor microenvironment for enhanced cancer immunotherapy

Y Xu, J Xiong, X Sun, H Gao - Acta Pharmaceutica Sinica B, 2022 - Elsevier
Cancer immunotherapy has significantly flourished and revolutionized the limited
conventional tumor therapies, on account of its good safety and long-term memory ability …